Melanoma News and Research RSS Feed - Melanoma News and Research

Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
Bim protein may hold clue for immunotherapy response in metastatic melanoma patients

Bim protein may hold clue for immunotherapy response in metastatic melanoma patients

A protein called Bim may hold the clue to which patients may be successful on immunotherapy for metastatic melanoma, according to the results of a study by Mayo Clinic researchers led by senior author Haidong Dong, M.D., Ph.D., and published online in the May 5 edition of JCI Insight. [More]
New investigational inhibitor JQEZ5 can block specific molecular malfunctions driving cancer

New investigational inhibitor JQEZ5 can block specific molecular malfunctions driving cancer

In a step forward in the push for targeted treatments that can block the specific molecular malfunctions driving cancer, University of North Carolina Lineberger Comprehensive Cancer Center researchers have demonstrated how a genetic mutation can drive the most common type of lymphoma as well as melanoma, the deadliest form of skin cancer. [More]
LJI study could provide important target for autoimmune disease interventions

LJI study could provide important target for autoimmune disease interventions

Follicular helper T cells (Tfh cells), a rare type of T cells, are indispensable for the maturation of antibody-producing B cells. They promote the proliferation of B cells that produce highly selective antibodies against invading pathogens while weeding out those that generate potentially harmful ones. [More]
Key method to test compounds for anti-cancer activity in cells flawed, study reveals

Key method to test compounds for anti-cancer activity in cells flawed, study reveals

The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers report May 2 in Nature Methods. The findings cast doubt on methods used by the entire scientific enterprise and pharmaceutical industry to discover new cancer drugs. [More]
NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges. [More]
Men need to brush up on their knowledge of skin cancer

Men need to brush up on their knowledge of skin cancer

Skin cancer can affect anyone, regardless of age, race or gender. When it comes to skin cancer prevention and detection, however, it seems that men need to brush up on their knowledge. [More]
Protea signs license agreement with Yale to develop new technology for detecting malignant melanoma

Protea signs license agreement with Yale to develop new technology for detecting malignant melanoma

Protea Biosciences Group, Inc. announced today that it had entered into an exclusive license agreement with Yale University for new technology to improve the differential diagnosis of malignant melanoma. [More]
Derivatives of female sex hormones can influence natural melanin production, study suggests

Derivatives of female sex hormones can influence natural melanin production, study suggests

When skin cells responsible for pigmentation are exposed to estrogen or progesterone, the cells respond by adjusting their melanin production, resulting in either skin darkening or lightening. Although pregnant women often experience alterations in skin pigmentation, the reason for the changes has long puzzled physicians. [More]
Drugs that block NOTCH signaling in many cancers could be effective against ACC

Drugs that block NOTCH signaling in many cancers could be effective against ACC

Using a novel cell culture approach, Yale Cancer Center researchers have discovered critical vulnerabilities in adenoid cystic carcinoma (ACC), a rare and lethal glandular cancer with a high recurrence rate and few treatment options. [More]
EADV's Global Call to Action urges policy makers to protect Europe’s outdoor workers from UV-induced skin cancer

EADV's Global Call to Action urges policy makers to protect Europe’s outdoor workers from UV-induced skin cancer

The European Academy of Dermatology and Venereology launched a Global Call to Action urging policy makers, employers, workers’ organisations and physicians to protect Europe’s outdoor workers from skin cancer caused by solar UV-radiation. [More]
KEYNOTE-001 findings add support to pembrolizumab for advanced melanoma

KEYNOTE-001 findings add support to pembrolizumab for advanced melanoma

A third of patients with advanced or metastatic melanoma will achieve an objective response to treatment with the programmed cell death protein inhibitor pembrolizumab, suggest KEYNOTE-001 findings, regardless of whether they have previously been treated with ipilimumab. [More]
Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

In a clinical trial of the immunotherapy drug pembrolizumab, half of 25 patients with a rare type of virus-linked skin cancer called Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long, on average, than with conventional chemotherapy. [More]
Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy. [More]
Mouse model can help identify new, more effective melanoma-preventing agents

Mouse model can help identify new, more effective melanoma-preventing agents

Application of sun protection factor 30 (SPF30) sunscreen prior to exposure to ultraviolet-B (UVB) light delayed melanoma onset in a mouse model of the disease, according to data from a team at The Ohio State University Comprehensive Cancer Center Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. This data suggest that the mouse model can be used to identify new, more effective melanoma-preventing agents, according to principal investigator Christin Burd, PhD. [More]
Genetic modification of common virus gives extra weapon to kill cancer cells

Genetic modification of common virus gives extra weapon to kill cancer cells

A common flu virus could be used to overcome patients' resistance to certain cancer drugs -- and improve how those drugs kill cancer cells, according to new research from Queen Mary University of London. [More]
Aged tumor cells in melanoma behave in a different way than younger tumor cells

Aged tumor cells in melanoma behave in a different way than younger tumor cells

Cancer risk increases with one's age as accumulated damage to our cells and chronic inflammation occur over time. Now, an international team of scientists led by The Wistar Institute have shown that aged tumor cells in melanoma behave differently than younger tumor cells, according to study results published in the journal Nature. [More]
HDAC inhibitors could improve activity of immunotherapeutic antibodies in lung cancer patients

HDAC inhibitors could improve activity of immunotherapeutic antibodies in lung cancer patients

Several new immunotherapeutic antibodies that inhibit checkpoint receptors on T cells to restimulate the immune system to target tumors have been approved to treat advanced stage lung cancer and melanoma; however, only 20 percent of lung cancer patients show a response to these agents. [More]
New tool interprets whole-exome tumor sequencing data for better cancer therapies

New tool interprets whole-exome tumor sequencing data for better cancer therapies

A University of Colorado Cancer study published today in the Journal of the American Medical Informatics Association describes a new tool that interprets the raw data of whole exome tumor sequencing and then matches the cancer's unique genetics to FDA-approved targeted treatments. [More]
Kevin Rudi Superhero 5K Fun Run to raise money for sarcoma research

Kevin Rudi Superhero 5K Fun Run to raise money for sarcoma research

The second annual Kevin Rudi Superhero 5K Fun Run will start and end by the Memorial Stadium Field House in Las Cruces. Money raised for sarcoma research will benefit The University of New Mexico Comprehensive Cancer Center. [More]

Outdoor workers in Europe at increased risk of developing non-melanoma skin cancer

There are almost 14.5 million workers in Europe, who spend at least 75% of their working time under the sun. [More]
Advertisement
Advertisement